SMStephen A. Martin

Stephen A. Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen A. Martin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Chelsea M. Heveran

    Department of Mechanical & Industrial Engineering, Montana State University, Bozeman, USA

    2 shared publications
  • Kenna Brown

    Department of Mechanical and Industrial Engineering, Montana State University, Bozeman, MT, USA

    2 shared publications
  • Adam J. Branscum

    Biostatistics Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR 97331, USA

    1 shared publication
  • Allan M. Aguirre-Burk

    Skeletal Biology Laboratory, School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR 97331, USA

    1 shared publication
  • Carmen P. Wong

    Skeletal Biology Laboratory, School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR 97331, USA

    1 shared publication
  • Connor C Devine

    Chemical and Biological Engineering Department Bozeman, MT 59718 , United States

    1 shared publication

Latest Publications

  • Open Access

    Bone microarchitecture and material properties decline differently across midlife for male and female F344 × BN F1 rats

    by Hunter Hasskamp, Emelia Keim, Kenna Brown, Sarah Sucher, Chelsea M. Heveran, Stephen A. Martin

    While bone mineral density (BMD) remains the clinical standard for assessing age-related fracture risk, accumulating evidence indicates that bone quality, including matrix properties and microarchitecture, contributes to fracture susceptibility in ways not captured by BMD alone. As matrix-targeted therapeutics emerge, preclinical models that exhibit translationally relevant bone quality changes are needed. Here, we evaluated the Fischer 344 × Brown Norway (F344×BN) F1 rat, a strain characterized by hybrid vigor and non-pathological aging, as a model for studying matrix-related mechanisms of skeletal aging. Femurs from male and female rats aged 7, 15, and 22 months were analyzed to quantify age- and sex-dependent changes in bone microarchitecture, fracture resistance, and matrix properties. Microcomputed tomography analyses revealed sexually dimorphic aging trajectories. From 7 to 22 months, females exhibited moderate declines in trabecular microarchitecture and no change in cortical porosity, whereas males showed pronounced trabecular deterioration and increased cortical porosity. Whole-bone flexural testing demonstrated age-related declines in material properties that were not attributable to changes in geometry, while females maintained geometry-scaled bone strength. Both sexes exhibited reduced bone toughness with age. Raman spectroscopy identified matrix-level alterations in males by 15 months, whereas systemic markers of bone turnover remained unchanged across age or sex. Together, these findings indicate that males exhibit combined tissue-scale and whole-bone deterioration by midlife, while females exhibit declining fracture resistance preceding substantial cortical bone loss or overt matrix deterioration. These results support the F344×BN F1 rat as a translational model for investigating matrix-driven skeletal aging. Lay summary: F344 x BN F1 hybrid rats provide a healthy, matrix-driven skeletal aging model. This strain exhibits distinct aging trajectories dependent on sex. Strength and toughness decrease in both sexes by midlife. Fracture resistance declines in females prior to substantial bone loss.

  • Open Access

    Rapamycin does not alter bone microarchitecture or material properties quality in young-adult and aged female C57BL/6 mice

    by Connor C Devine, Kenna C Brown, Kat O Paton, Chelsea M Heveran, Stephen A Martin

    Advancing age is the strongest risk factor for osteoporosis and skeletal fragility. Rapamycin is an FDA-approved immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) complex, extends lifespan, and protects against aging-related diseases in multiple species; however, the impact of rapamycin on skeletal tissue is incompletely understood. We evaluated the effects of a short-term, low-dosage, interval rapamycin treatment on bone microarchitecture and strength in young-adult (3 mo old) and aged female (20 mo old) C57BL/6 mice. Rapamycin (2 mg/kg body mass) was administered via intraperitoneal injection 1×/5 d for a duration of 8 wk; this treatment regimen has been shown to induce geroprotective effects while minimizing the side effects associated with higher rapamycin dosages and/or more frequent or prolonged delivery schedules. Aged femurs exhibited lower cancellous bone mineral density, volume, trabecular connectivity density and number, higher trabecular thickness and spacing, and lower cortical thickness compared to young-adult mice. Rapamycin had no impact on assessed microCT parameters. Flexural testing of the femur revealed that both yield strength and ultimate strength were lower in aged mice compared to young-adult mice. There were no effects of rapamycin on these or other measures of bone biomechanics. Age, but not rapamycin, altered local and global measures of bone turnover. These data demonstrate that short-term, low-dosage interval rapamycin treatment does not negatively or positively impact the skeleton of young-adult and aged mice.


  • Open Access

    Rapamycin impairs bone accrual in young adult mice independent of Nrf2

    by Stephen A. Martin, Ruben T. Riordan, Rong Wang, Zhen Yu, Allan M. Aguirre-Burk, Carmen P. Wong, Dawn A. Olson, Adam J. Branscum, Russell T. Turner, Urszula T. Iwaniec, et al.